ADMA Biologics to Report Second Quarter 2021 Financial Results on August 11, 2021
ADMA Biologics, a biopharmaceutical company specializing in plasma-derived biologics, will announce its second-quarter financial results on August 11, 2021, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics, a biopharmaceutical company specializing in plasma-derived biologics, will announce its second-quarter financial results on August 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET for discussion of the results and company updates. ADMA's products include ASCENIV™, BIVIGAM®, and NABI-HB®, all FDA-approved for treating immunodeficient patients. The company’s manufacturing is based in Boca Raton, Florida, and it operates FDA-approved plasma collection centers to support its production.
Positive
- ADMA's FDA-approved products cater to niche patient populations with immune deficiencies.
- Company operates its own FDA-licensed plasma fractionation facility, enhancing production control.
Negative
- None.
Details
News Market Reaction – ADMA
The recorded move for ADMA in the trading session of this news was -4.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for August 11, 2021 at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call, please dial (855) 884-8773 (local) or (615) 622-8043 (international) at least 10 minutes prior to the start time and refer to conference ID 8992329. A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website approximately two hours after the event.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
COMPANY CONTACT:
Skyler Bloom
Director, Investor Relations and Corporate Strategy | 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Michelle Pappanastos
Senior Managing Director, Argot Partners | 212-600-1902 | michelle@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.